ArgenTAG

Executive Summary

ArgenTAG is a San Diego-based private company developing the first single-cell RNA library kit specifically designed for long-read sequencing platforms from Oxford Nanopore and PacBio. Founded in 2016, the company addresses a critical gap in transcriptomics by enabling full-length isoform resolution at single-cell resolution, which is not possible with short-read sequencing. Their end-to-end solution aims to democratize long-read single-cell studies, allowing researchers to achieve high-resolution transcriptome profiling in their own labs. The early access program, currently open, signals initial product validation and customer feedback gathering. Operating at the intersection of single-cell genomics and long-read technology, ArgenTAG targets the rapidly growing single-cell sequencing market, valued at over $3 billion, with applications in infectious disease, oncology, and developmental biology. While the company has not disclosed funding or revenue, its focus on a niche but expanding technical need positions it favorably for partnerships or acquisition by larger genomics tool providers.

Upcoming Catalysts (preview)

• Q3 2026Full commercial launch of single-cell RNA library kit following early access feedback70% success
• Q4 2026Strategic partnership with major sequencing platform provider (e.g., PacBio or Oxford Nanopore) for co-marketing or distribution50% success
• Q1 2027Series A funding round led by life sciences VC to scale production and sales60% success